Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Neurogastrx is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Omara played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neurogastrx
We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.

To learn more about Neurogastrx, visit http://neurogastrx.com/

Contact:
James Omara, Chief Executive Officer
781-730-4606
jomara@neurogastrx.com
https://www.linkedin.com/in/james-o-mara-48704bb/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved